1. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
   Kazuhiko Yamada et al, 2016, Cancer Chemotherapy and Pharmacology CrossRef
2. Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer
   Tsukasa Hasegawa et al, 2021, International Journal of Clinical Oncology CrossRef
3. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors
   Hui-Jen Tsai et al, 2021, Scientific Reports CrossRef
4. Downregulation of p38 MAPK Activation and Radiation-Sensitive 52 Expression Enhances 5-Fluorouracil and Erlotinib-Induced Cytotoxicity in Human Lung Squamous Cells
   Jen-Chung Ko et al, 2021, Pharmacology CrossRef
5. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer
   Kyoichi Kaira et al, 2013, Lung Cancer CrossRef
6. Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts
   Yukimasa Makita et al, 2018, Oncology Letters CrossRef
7. The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients
   Long Yan et al, 2019, Medicine CrossRef
8. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review
   Alessia Belloni et al, 2024, Critical Reviews in Oncology/Hematology CrossRef
9. Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer
   Yoshiko Urata et al, 2013, Cancer CrossRef
10. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202)
    Akihiko Miyanaga et al, 2019, Japanese Journal of Clinical Oncology CrossRef
11. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)
    null null et al, 2016, Cancer Chemotherapy and Pharmacology CrossRef
12. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)
    Kazumi Nishino et al, 2015, Lung Cancer CrossRef
13. Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts
    Hideki Nagase et al, 2018, Chemotherapy CrossRef
14. Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
    Hiroyuki Suzuki et al, 2021, Translational Oncology CrossRef
15. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
    Kazuaki Matsuoka et al, 2018, International Journal of Molecular Sciences CrossRef
16. Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
    Diane‐Charlotte Imbs et al, 2018, CPT: Pharmacometrics & Systems Pharmacology CrossRef
17. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Jun Taguchi et al, 2021, International Journal of Clinical Oncology CrossRef